1. Home
  2. MDXH vs ASRT Comparison

MDXH vs ASRT Comparison

Compare MDXH & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • ASRT
  • Stock Information
  • Founded
  • MDXH 2003
  • ASRT 1995
  • Country
  • MDXH Belgium
  • ASRT United States
  • Employees
  • MDXH N/A
  • ASRT N/A
  • Industry
  • MDXH
  • ASRT Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDXH
  • ASRT Health Care
  • Exchange
  • MDXH Nasdaq
  • ASRT Nasdaq
  • Market Cap
  • MDXH 100.5M
  • ASRT 105.8M
  • IPO Year
  • MDXH 2021
  • ASRT 1997
  • Fundamental
  • Price
  • MDXH $1.77
  • ASRT $0.84
  • Analyst Decision
  • MDXH Strong Buy
  • ASRT Strong Buy
  • Analyst Count
  • MDXH 2
  • ASRT 4
  • Target Price
  • MDXH $7.00
  • ASRT $3.19
  • AVG Volume (30 Days)
  • MDXH 98.8K
  • ASRT 814.4K
  • Earning Date
  • MDXH 11-06-2024
  • ASRT 11-11-2024
  • Dividend Yield
  • MDXH N/A
  • ASRT N/A
  • EPS Growth
  • MDXH N/A
  • ASRT N/A
  • EPS
  • MDXH N/A
  • ASRT N/A
  • Revenue
  • MDXH $84,708,000.00
  • ASRT $125,763,000.00
  • Revenue This Year
  • MDXH $26.39
  • ASRT N/A
  • Revenue Next Year
  • MDXH $18.68
  • ASRT $4.68
  • P/E Ratio
  • MDXH N/A
  • ASRT N/A
  • Revenue Growth
  • MDXH 33.01
  • ASRT N/A
  • 52 Week Low
  • MDXH $0.35
  • ASRT $0.73
  • 52 Week High
  • MDXH $4.64
  • ASRT $1.80
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 26.20
  • ASRT 32.60
  • Support Level
  • MDXH $1.62
  • ASRT $0.82
  • Resistance Level
  • MDXH $2.24
  • ASRT $1.07
  • Average True Range (ATR)
  • MDXH 0.13
  • ASRT 0.07
  • MACD
  • MDXH -0.01
  • ASRT -0.02
  • Stochastic Oscillator
  • MDXH 28.57
  • ASRT 13.09

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: